Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$18.53 +6.0%	$13.96	$8.04 ▼ $25.88	$501.46M	2.26	474,014 shs	337,723 shs
HURA TuHURA Biosciences	$3.21 +10.4%	$2.60	$1.80 ▼ $8.40	$160.65M	0.04	308,000 shs	531,234 shs
SNDL SNDL	$2.26 +0.7%	$1.55	$1.15 ▼ $2.40	$592.57M	3.57	2.17 million shs	2.14 million shs
ZVRA Zevra Therapeutics	$9.51 -0.1%	$10.55	$6.19 ▼ $13.16	$533.80M	1.87	750,610 shs	697,156 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+0.69%	-9.10%	+20.30%	+43.28%	-20.11%
HURA TuHURA Biosciences	-2.35%	+5.43%	+6.20%	+2.83%	+290,999,900.00%
SNDL SNDL	+1.36%	+6.16%	+36.59%	+73.64%	+6.16%
ZVRA Zevra Therapeutics	+2.48%	+6.85%	-17.88%	+9.94%	+26.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	2.9903 of 5 stars	3.5	2.0	3.4	2.5	0.6
HURA TuHURA Biosciences	1.6136 of 5 stars	3.7	0.0	2.1	0.0	0.0
SNDL SNDL	1.7993 of 5 stars	2.0	3.0	2.4	0.0	1.3
ZVRA Zevra Therapeutics	3.4913 of 5 stars	4.5	3.0	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.00	Buy	$50.57	172.89% Upside
HURA TuHURA Biosciences	3.40	Buy	$12.67	294.23% Upside
SNDL SNDL	0.00	N/A	$4.00	77.38% Upside
ZVRA Zevra Therapeutics	3.00	Buy	$23.71	149.49% Upside

Current Analyst Ratings Breakdown

Latest HURA, SNDL, ZVRA, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	ARCT Arcturus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$63.00 ➝ $54.00
8/18/2025	ZVRA Zevra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/13/2025	ZVRA Zevra Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $18.00
8/12/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $49.00
8/12/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $42.00
7/10/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/23/2025	HURA TuHURA Biosciences	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	3.30	N/A	N/A	$8.51 per share	2.18
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.38 per share	N/A
SNDL SNDL	$671.81M	0.88	N/A	N/A	$2.99 per share	0.75
ZVRA Zevra Therapeutics	$23.61M	22.60	N/A	N/A	$2.09 per share	4.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.23	N/A	N/A	N/A	-49.26%	-24.87%	-17.75%	11/6/2025 (Estimated)
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	-248.79%	-150.83%	10/6/2025 (Estimated)
SNDL SNDL	-$69.18M	-$0.27	N/A	N/A	N/A	-10.38%	-8.58%	-7.23%	11/4/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$0.21	N/A	47.53	N/A	4.33%	-112.40%	-37.67%	N/A

Latest HURA, SNDL, ZVRA, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	HURA TuHURA Biosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A
8/11/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	-$0.34	+$0.77	-$0.34	$17.64 million	$28.30 million
7/31/2025	Q2 2025	SNDL SNDL	-$0.04	$0.01	+$0.05	$0.01	$231.50 million	$179.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.90	5.90
HURA TuHURA Biosciences	N/A	0.83	3.00
SNDL SNDL	0.11	5.03	3.36
ZVRA Zevra Therapeutics	0.52	7.85	7.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
HURA TuHURA Biosciences	0.62%
SNDL SNDL	N/A
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
HURA TuHURA Biosciences	0.20%
SNDL SNDL	N/A
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.16 million	22.65 million	Optionable
HURA TuHURA Biosciences	N/A	50.05 million	49.95 million	N/A
SNDL SNDL	2,516	262.78 million	N/A	Optionable
ZVRA Zevra Therapeutics	20	56.13 million	54.79 million	Optionable

HURA, SNDL, ZVRA, and ARCT Headlines

Recent News About These Companies

Zacks Research Downgrades Zevra Therapeutics (NASDAQ:ZVRA) to Hold

August 22 at 9:59 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Sees Strong Trading Volume Following Insider Buying Activity

August 22 at 2:47 AM | americanbankingnews.com

Zevra Therapeutics rumor highlighted in Betaville blog

August 21 at 2:56 PM | msn.com

Zevra Therapeutics gains amid takeover speculation

August 21 at 2:56 PM | msn.com

Zevra Therapeutics (NASDAQ:ZVRA) Director John Bode Buys 5,000 Shares

August 21 at 8:54 AM | insidertrades.com

Tourmaline Bio (NASDAQ:TRML) versus Zevra Therapeutics (NASDAQ:ZVRA) Head to Head Review

August 20 at 2:09 AM | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 4.4% - Should You Buy?

August 17, 2025 | marketbeat.com

Cantor Fitzgerald Brokers Lower Earnings Estimates for ZVRA

August 17, 2025 | marketbeat.com

Equities Analysts Offer Predictions for ZVRA Q3 Earnings

August 17, 2025 | marketbeat.com

Q3 EPS Forecast for Zevra Therapeutics Increased by Analyst

August 17, 2025 | marketbeat.com

HC Wainwright Has Bearish Estimate for ZVRA FY2027 Earnings

August 16, 2025 | marketbeat.com

Cantor Fitzgerald Brokers Cut Earnings Estimates for ZVRA

August 16, 2025 | americanbankingnews.com

Q3 EPS Estimate for Zevra Therapeutics Lifted by Analyst

August 16, 2025 | americanbankingnews.com

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)

August 15, 2025 | zacks.com

Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down on Analyst Downgrade

August 15, 2025 | marketbeat.com

JMP Securities Lowers Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $18.00

August 15, 2025 | marketbeat.com

JMP Securities Has Lowered Expectations for Zevra Therapeutics (NASDAQ:ZVRA) Stock Price

August 15, 2025 | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Releases Quarterly Earnings Results, Misses Estimates By $0.71 EPS

August 14, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Altium Capital Management LLC's Largest Position

August 14, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down Following Analyst Downgrade

August 14, 2025 | americanbankingnews.com

Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability

August 14, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA, SNDL, ZVRA, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$18.53 +1.05 (+6.02%)

As of 03:45 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

TuHURA Biosciences NASDAQ:HURA

$3.21 +0.30 (+10.41%)

As of 03:45 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

SNDL NASDAQ:SNDL

$2.26 +0.02 (+0.67%)

As of 03:44 PM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

Zevra Therapeutics NASDAQ:ZVRA

$9.51 -0.01 (-0.05%)

As of 03:44 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time